# BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

> **NCT04318327** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 96 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** PHE885

## Key facts

- **NCT ID:** NCT04318327
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-23
- **Primary completion:** 2025-04-29
- **Final completion:** 2025-04-29
- **Target enrollment:** 96 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04318327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04318327, "BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04318327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*